Sugi Predict

Sugi Predict / Compounds / SCHEMBL355461

SCHEMBL355461

SCHEMBL355461

CC(C)(C)OC(=O)c1ccc(N)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51
▸ ALOX15 P16050 1/20 0.47
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ GABRA1 P14867 1/20 0.43
▸ GABRG2 P18507 1/20 0.43
▸ GABRB3 P28472 1/20 0.43
▸ GABRA3 P34903 1/20 0.43
▸ GABRA2 P47869 1/20 0.43
▸ SLC7A5 Q01650 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23093930 0.87 ALOX15 (0.50) ALOX15CA12CA1CA2CA9
SCHEMBL11090176 0.84 ALOX15 (0.53) ALOX15CA12CA1CA2CA9
SCHEMBL4208340 0.84 CES2 (0.53) ALOX15CA12CA1CA2CA9
SCHEMBL30208191 0.84 CES2 (0.53) ALOX15CA12CA1CA2CA9
SCHEMBL4816280 0.81 HDAC1 (0.53) HDAC1HDAC6ALOX15CA12CA1
SCHEMBL31587898 0.81 CA12 (0.46) ALOX15CA12CA1CA2CA9
SCHEMBL1028144 0.81 ALOX15 (0.48) ALOX15CA12CA1CA2CA9
SCHEMBL9470701 0.81 CA12 (0.50) ALOX15CA12CA1CA2CA9
SCHEMBL7472823 0.81 ALOX15 (0.48) ALOX15CA12CA1CA2CA9
SCHEMBL1457756 0.81 KDM4E (0.61) HDAC1HDAC6ALOX15CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041782-A1 ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Shanghai Ruotuo Biosciences (CN) 2026-02-12 — — US disclosed
EP-4568954-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF Insilico Medicine IP Limited (HK) 2025-06-18 — — EP disclosed
CN-115066417-B Factor XIa inhibitors 上海京新生物医药有限公司 2025-05-02 — — CN disclosed
CN-119677729-A Cyclin Dependent Kinase (CDK) 12 and/or CDK13 inhibitors and uses thereof 英矽智能科技知识产权有限公司 2025-03-21 — — CN disclosed
CN-118453896-A Antibody-drug conjugates, pharmaceutical compositions and therapeutic uses 上海偌妥生物科技有限公司 2024-08-09 — — CN disclosed
WO-2024037503-A1 ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS SHANGHAI RUOTUO BIOSCIENCES CO., LTD. (CN) 2024-02-22 — — WO disclosed
WO-2024032561-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2024-02-15 — — WO disclosed
CN-115066417-A Factor XIa inhibitors 上海京新生物医药有限公司 2022-09-16 — — CN disclosed
WO-2021203023-A1 INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 — — WO disclosed
WO-2021136390-A1 BLOOD COAGULATION FACTOR XIA INHIBITOR 上海京新生物医药有限公司 2021-07-08 — — WO disclosed
US-9434690-B2 Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-06 — — US disclosed
US-9434690-B2 Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-06 — — US disclosed
US-20160052884-A1 Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 — — US disclosed
CN-105164122-A Substituted oxopyridine derivatives and their use in the treatment of cardiovascular disorders Bayer Pharma AG 2015-12-16 — — CN disclosed
WO-2015052675-A1 SUBSTITUTED DIHYDRO-BENZIMIDAZOLE COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2015-04-16 — — WO disclosed
WO-2014154794-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-10-02 — — WO disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 — — EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041782-A1 ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS FCGRT, FCGR2A, NR3C1 HDAC1 2096/4885HDAC6 808/4885ALOX15 3279/4885
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 HDAC1 1315/4885HDAC6 2235/4885ALOX15 2291/4885
US-20160052884-A1 Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders OGFOD1, PNPO, VASP HDAC1 4133/4885HDAC6 4482/4885ALOX15 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.